Core Viewpoint - The company, Gilead Sciences (1672.HK), announced a share buyback plan, which has led to a nearly 13% increase in its stock price, reflecting confidence in its long-term business prospects and growth potential [1] Group 1: Share Buyback Announcement - The company plans to utilize up to 300 million HKD from its internal financial resources for the proposed share buyback [1] - The buyback authorization allows the company to repurchase up to 96.2846 million shares, representing 10% of the total issued shares [1] - The board believes that the share buyback will enhance shareholder value and returns [1] Group 2: Financial Health and Confidence - The company stated that its current financial condition is stable [1] - The proposed buyback reflects the company's confidence in its long-term business outlook and growth potential [1] - The company will ensure that the buyback does not significantly adversely affect its operating capital [1]
歌礼制药拉升涨近13%，拟斥最多3亿元回购股份